The global medical industry experienced a 12% rise in company filings mentions of regenerative medicine in Q2 2023 compared with the previous quarter, with the highest share accounted for by Bio-Techne with 12% year-on-year increase, according to GlobalData’s analysis of over 72 medical company filings. GlobalData’s Regenerative Medicine in Medical thematic intelligence report provides an overview of the current landscape, including healthcare, technology, regulatory, macroeconomic trends, and key players. Buy the report here.
Notably, regenerative medicine was one of the most frequently referenced themes in Q2 2023, ranking highest in terms of mentions, ahead of edtech and metaverse, according to GlobalData.
Of the top leading companies in the medical industry, Bio-Techne had the greatest increase in references for regenerative medicine in Q2 2023, compared with the previous quarter. GlobalData identified 19 regenerative medicine-related sentences in the company's filings - 2% of all sentences - and an increase of 12% in Q2 2023 compared with Q2 2022. Cooper’s mentions of regenerative medicine rose by 88% to 15 and Thermo Fisher Scientific’s by 400% to 10 and Illumina’s by 100% to 2 and Agilent Technologies’s by 50% to 1.
GlobalData’s Company Filings Analytics also applies sentiment weight to reference sentences, based on whether the sentences are positive, negative, or neutral. Starting at 100 in 2020, an index over 100 is more positive. The overall index for regenerative medicine in Q2 2023 was 97.
For further understanding of GlobalData's Regenerative Medicine in Medical - Thematic Research buy the report here.